Skip to main content

Table 1 Comparisons of Baseline Demographics and Clinicopathological Characteristics between the RT and Control groups

From: Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study

Characteristics

RT (n = 29)

Control (n = 30)

p value

Age (year)

55.90 ± 8.05

56.57 ± 9.43

0.771

Gender (Male/Female)

24/5

25/5

1.000

Operative time (min)

229.17 ± 75.77

224.00 ± 78.12

0.797

Blood loss (ml)

384.48 ± 317.38

372.67 ± 246.49

0.873

Operative procedure (Major/Minor)

9/20

7/23

0.506

Operative method (Anatomical/Non-anatomical)

14/15

12/18

0.522

Surgical margin (< 0.5 cm / ≥0.5 cm)

19/10

16/14

0.341

Tumor size (cm)

4.75 ± 2.15

4.50 ± 2.98

0.712

Number of tumor (single/multiple)

27/2

28/2

1.000

Differentiation (Well-Moderate/Poorly)

17/12

12/18

0.153

Tumor growth pattern (nodular / diffuse)

29/0

30/0

–

MVI classification (M1/M2)

19/10

21/9

0.713

Envelope invasion (Present/Absent)

14/15

13/17

0.703

Fibrosis Scheuer S score (< 3 /≥3)

14/15

12/18

0.522

HBV-Ag (Negative/Positive)

5/24

3/27

0.417

Preoperative AFP level (Negative/≦400 ng/L / > 400 ng/)

6/16/7

7/16/7

0.970

Preoperative ALT level (U/L)

30.55 ± 18.79

32.67 ± 20.78

0.684

Preoperative TBIL level (umol/L)

13.40 ± 5.32

15.49 ± 6.66

0.188

Preoperative ALB level (g/L)

44.45 ± 3.55

42.72 ± 4.54

0.111

Preoperative PTa level (%)

83.79 ± 11.08

83.81 ± 10.93

0.996

  1. Variables are expressed as the mean ± SD (median with range) or no. (%) (number with percentages), unless otherwise indicated;
  2. AFP alpha-fetoprotein; ALT alanine aminotransferase; TBIL total bilirubin; ALB albumin; PTa prothrombin time